Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Show more

Location: 2749 East Parleys Way, Salt Lake City, UT, 84109, United States | Website: https://www.sera.com | Industry: Medical Devices | Sector: Healthcare


Market Cap

107M

52 Wk Range

$1.37 - $9.13

Previous Close

$2.76

Open

$2.77

Volume

59,444

Day Range

$2.71 - $2.84

Enterprise Value

58.72M

Cash

46.2M

Avg Qtr Burn

-6.684M

Insider Ownership

11.53%

Institutional Own.

69.95%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date